2022 World Conference on Lung Cancer (ePosters)-EP16.02-029. Plasma-Based Next Generation Sequencing for Molecular Characterization of Lung Adenocarcinoma: A Multicentric Cohort From Argentina

EP16.02-029. Plasma-Based Next Generation Sequencing for Molecular Characterization of Lung Adenocarcinoma: A Multicentric Cohort From Argentina

Back to course

Pdf Summary

A multicentric cohort from Argentina conducted a study on the use of plasma-based next-generation sequencing (NGS) for molecular characterization of lung adenocarcinoma. The study focused on the use of liquid biopsy as a non-invasive and feasible alternative for genotyping non-small cell lung cancer (NSCLC). The researchers analyzed a cohort of patients with advanced NSCLC who underwent liquid biopsy using the FoundationLiquidCDx test at diagnosis or disease progression to tyrosine kinase inhibitors (TKI) in EGFR/ALK from June to December 2020. They described the molecular alterations and oncogenicity of the genomic variants identified, categorized the alterations found in potentially actionable genes and non-actionable genes, and assessed the frequency correlations between the cohorts using Fisher's exact tests. The study also identified potential germline alterations and described the resistance mechanisms at progression to TKI. The most frequent molecular alterations identified in the ctDNA of all patients included KRAS, NF1, EGFR, ALK, MET, BRAF, PTEN, CDKN2A, ERBB2, CDK12, FGFR, ROS1, MTOR, TP53, STK11, ASXL1, TET2, CHEK2, BRCA1, APC, GNAS, JAK2, NOTCH, RAF1, EPHA3, MLL2, TBX3, and CDX4. The study also provided information on patient characteristics such as age, gender, smoking status, and Eastern Cooperative Oncology Group Performance Status (ECOG PS). Overall, this study demonstrated the potential of plasma-based NGS for molecular characterization of lung adenocarcinoma and its implications for treatment decisions and patient management.

Asset Subtitle

Martina Paz Spotti

Meta Tag

Speaker Martina Paz Spotti

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

Argentina

plasma-based NGS

lung adenocarcinoma

liquid biopsy

NSCLC

genomic variants

tyrosine kinase inhibitors

potentially actionable genes

resistance mechanisms

patient management